Novartis receives approval for further Pluvicto production in the USA
Published: Friday, Jan 5th 2024, 16:10
Zurück zu Live Feed
Novartis has received further approval from the US Food and Drug Administration (FDA) for the production of the radioligand therapy Pluvicto. In future, Pluvicto doses will be manufactured in a 70,000 square meter, state-of-the-art facility at the Indianapolis site, Novartis announced on Friday
Pluvicto is used to treat prostate cancer and Novartis' plans include a significant expansion of production of this therapy in order to meet the high global demand. The plant in Indiana is the second in the USA and production is also underway in Italy and Spain. Plants in Japan and China are also being planned.
In 2024 and beyond, Novartis plans to increase the production capacity of Pluvicto to up to 250,000 doses per year. The therapy has blockbuster potential. In the third quarter alone, Novartis generated sales of almost USD 260 million with the sale of Pluvicto.
©Keystone/SDA
German 
English 
French 
Spanish 
Arabic